are known molecular targets for a wide range of indications, Isotechnika will use the funding from IRAP to support the identification and selection of lead candidates for neuroprotection at this time.
An essential cell factor required for hepatitis C virus replication is cyclophilin
, which promotes the proper folding of proteins and the formation of large protein assemblies, adds the report.
SCY-635, a novel cyclophilin
inhibitor, represents a new pharmacological class of inhibitors of hepatitis C virus (HCV) replication.
LAUSANNE, Switzerland, April 19 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, presented additional results of a previous phase Ib, 15 day study with cyclophilin
(Cyp) inhibitor Debio 025 in HIV/HCV (hepatitis C virus) co-infected patients.
Cyclosporin works by first attaching to a protein called cyclophilin
LAUSANNE, Switzerland, October 31 /PRNewswire/ -- The Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions, today presented results from a phase Ib study of cyclophilin
inhibitor Debio-025, in treatment-naive HIV/HCV (hepatitis C virus) co-infected patients.
Others account for these differences by pointing to the existence of a limiting factor, the active immunophilins present in the lymphocytes; it appears that active FKBPs have a greater limiting effect than active cyclophilins
and peptidyl-prolyl cis-trans isomerase are probably identical proteins.
In the study, the role of 3-Sar ether and thioether groups were evaluated for binding to cyclophilins
A and B, immunosuppressive potential and HCV replicon activity.
A growing body of research has demonstrated the central role that cyclophilins
play in catalyzing the folding of proteins, and their inhibition is an exciting avenue for therapeutic intervention and drug discovery," said Dr.
The PPIA rs8177826 C>G SNP located in the promoter region of the gene coding cyclophilin
A, the intracellular receptor of cyclosporine (and not tacrolimus), decreases NFAT1IC50 and explains 37% of its interindividual variability.
today presented data demonstrating that SCY-635--a novel, oral cyclophilin
inhibitor being studied for the treatment of hepatitis C virus (HCV) infection--reactivates the body's natural defense mechanism, making it capable of inhibiting replication of the virus.